5-Azacytidine

DRUG18 trials

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), M.D. Anderson Cancer Center, Gruppo Italiano Malattie EMatologiche dell'Adulto, Virginia Commonwealth University, Novartis Pharmaceuticals

Conditions

AML, ChildhoodAcute Myelogenous LeukemiaAcute Myeloid LeukemiaBeta ThalassemiaBrain Tumor RecurrentCNS MalignanciesChronic Lymphocytic LeukemiaChronic Myelomonocytic Leukemia

Early Phase 1

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma

CompletedNCT02940483

The University of Texas Health Science Center, HoustonBrain Tumor Recurrent

Start: 2017-02-01End: 2018-11-28Updated: 2018-11-30

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

RecruitingNCT04187703

Benjamin TomlinsonMDS/MPN Crossover Syndromes, Myelodysplastic Syndromes

Start: 2020-11-16End: 2026-12-01Target: 20Updated: 2025-04-09

5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)

WithdrawnNCT06598332

Baylor College of MedicineGraft-Versus-Host Disease(GVHD)

Start: 2025-08-31End: 2029-05-01Updated: 2025-09-22

Phase 1

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

CompletedNCT00946647

Novartis PharmaceuticalsAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes

Start: 2009-12-02End: 2019-04-29Updated: 2020-08-04

5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

CompletedNCT01038635

M.D. Anderson Cancer CenterLeukemia

Start: 2009-12-31End: 2015-11-30Updated: 2017-02-10

PKC412 and 5-Azacytidine

CompletedNCT01202877

M.D. Anderson Cancer CenterLeukemia

Start: 2011-03-31End: 2015-07-31Updated: 2018-10-16

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

TerminatedNCT02096042

M.D. Anderson Cancer CenterLeukemia

Start: 2014-04-30End: 2016-08-31Updated: 2023-10-10

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

WithdrawnNCT02829840

M.D. Anderson Cancer CenterFLT3-Mutated Acute Myeloid Leukemia, FLT3-Mutated High-Risk Myelodysplastic Syndrome, Leukemia

Start: 2016-09-30Updated: 2017-06-02

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Therapeutic Advances in Childhood Leukemia ConsortiumAML, Childhood

Start: 2019-11-29End: 2024-03-30Updated: 2022-10-12

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

WithdrawnNCT06466798

Jeffrey TreiberCNS Malignancies, Recurrent Ependymoma, Recurrent Medulloblastoma

Start: 2024-07-15End: 2027-07-01Updated: 2026-01-08

Phase 2

5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia

CompletedNCT00005934

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Beta Thalassemia

Start: 2000-06-30End: 2003-06-30Target: 24Updated: 2008-03-04

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

CompletedNCT00382590

M.D. Anderson Cancer CenterAcute Myelogenous Leukemia, Leukemia, Myelodysplastic Syndrome

Start: 2005-08-31End: 2008-02-29Updated: 2012-08-07

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

TerminatedNCT00413478

M.D. Anderson Cancer CenterChronic Lymphocytic Leukemia, Leukemia

Start: 2006-09-30End: 2014-11-30Updated: 2015-06-30

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

CompletedNCT00439673

Gruppo Italiano Malattie EMatologiche dell'AdultoMyelodysplastic Syndromes

Start: 2007-05-31End: 2010-07-31Updated: 2018-08-07

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

CompletedNCT00721214

Virginia Commonwealth UniversityMyelodysplastic Syndrome

Start: 2008-07-31End: 2014-06-30Updated: 2016-03-02

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

TerminatedNCT00997243

Alison WalkerLeukemia, Myelodysplastic Syndromes

Start: 2009-11-30End: 2011-05-31Updated: 2017-05-10

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

CompletedNCT02497404

Weill Medical College of Cornell UniversityLeukemia, Erythroblastic, Acute, Myelodysplastic Syndromes

Start: 2015-02-13End: 2021-06-17Updated: 2021-09-22

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

RecruitingNCT05317000

Barbara BurtnessSquamous Cell Carcinoma of Head and Neck

Start: 2023-03-23End: 2028-11-30Target: 50Updated: 2026-01-12

Related Papers

Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Cancers2024-01-248 citations

Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with <i>In Vivo</i> T Cell Depletion: Results of a Phase II Trial

Blood2022-11-15

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

Clinical Cancer Research2022-11-0930 citations

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

2014-12-2220 citations